Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Blood (2023) 142 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2023-179767

Published: 2023

Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer

Blood (2023) 142 (Supplement 1): 199.

https://doi.org/10.1182/blood-2023-180558

Published: 2023

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

Blood (2022) 140 (Supplement 1): 9879–9881.

https://doi.org/10.1182/blood-2022-169956

Published: 2022

Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Blood (2022) 139 (2): 177–187.

https://doi.org/10.1182/blood.2021010845

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Blood (2021) 138 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2021-153200

Published: 2021

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Mathias J Rummel, Christian Buske, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Michael Koenigsmann, MD, Elisabeth Lange, MD, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Dirk Behringer, MD, Jan Dürig, MD, Tobias Gaska, MD, Georg Maschmeyer, MD, Georg Schliesser, MD, Alexander Christoph Burchardt, MD, Juergen Barth, Frank Kauff, Axel Hinke, PhD, Richard Greil, MD

Blood (2017) 130 (Supplement 1): 483.

https://doi.org/10.1182/blood.V130.Suppl_1.483.483

Published: 2017

Journal Articles

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial

Ulrich Duehrsen, MD, Stefan P Müller, MD, Jan Rekowski, Dipl.-Stat., Bernd Hertenstein, MD, Christiane Franzius, MD, Rolf Mesters, MD, Matthias Weckesser, MD, Frank Kroschinsky, MD, Jörg Kotzerke, MD, Anke Franzke, MD, Frank M Bengel, MD, Paul La Rosée, MD, Martin Freesmeyer, MD, Heinz-Gert Hoeffkes, MD, Andreas Hertel, MD, Dirk Behringer, Gabriele Prange-Krex, MD, Martin Griesshammer, MD, Jens Holzinger, MD, Stefan Wilop, MD, Thomas Krohn, MD, Aruna Raghavachar, MD, Georg Maschmeyer, MD, Ingo Brink, MD, Roland Schroers, MD, Tobias Gaska, MD, Tu-Anh Dang, MD, Aristoteles Giagounidis, Ariane Dienst, MD, Hubertus Hautzel, MD, Ralph Naumann, MD, Alfred Klein, MD, Dennis Hahn, MD, Gabriele Pöpperl, MD, Matthias Grube, MD, Jörg Marienhagen, MD, Andreas Schwarzer, MD, Lars Kurch, MD, Thomas Höhler, MD, Heike Steiniger, MD, Holger Nückel, MD, Thomas Südhoff, MD, Wolfgang Römer, MD, Marcus Brinkmann, Claudia Ose, Dieter Hoelzer, MD, Jan Dürig, MD, Karl-Heinz Jöckel, PhD, Wolfram Klapper, MD, Andreas Hüttmann, MD

Blood (2016) 128 (22): 1857.

https://doi.org/10.1182/blood.V128.22.1857.1857

Published: 2016

Journal Articles

Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

Blood (2014) 124 (21): 3052.

https://doi.org/10.1182/blood.V124.21.3052.3052

Published: 2014

Journal Articles

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)

Blood (2014) 124 (21): 391.

https://doi.org/10.1182/blood.V124.21.391.391

Published: 2014

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

Michael Pfreundschuh, MD, Marita Ziepert, Marcel Reiser, Viola Poeschel, Sibylla Wilhelm, Tobias Gaska, Michael Heike, Norbert Schmitz, Christian Ruebe, Markus Loeffler, Joerg Schubert

Blood (2008) 112 (11): 584.

https://doi.org/10.1182/blood.V112.11.584.584

Published: 2008

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

NARROW

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial

Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only